AstraZeneca's Rare Drug Trial Failure Sends Shares Plunging
Share
AstraZeneca Plc's shares dropped more than 10% after a trial of a new heart drug failed to help prevent heart problems in patients with a rare disease. Bloomberg Intelligence's Sam Fazeli has more on "Bloomberg Open Interest."
More from Australia
St Barbara restarts Touquoy ore processing in Canada
Woodside Energy outlines strategy targeting US$40B cash flow
News Corp posts US$2.28B first quarter revenue
REA Group Q1 revenue increases 11% to $450M
Light & Wonder Q3 net income lifts 17% to US$133M
National Australia Bank reports $6.14B in full-year profit